Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?

Indeed, with the exception of lixisenatide, all other GLP-1 RAs showed a trend toward a reduced incidence of MACEs (i.e., time to first event of either CV death or non-fatal myocardial infarction or stroke), which was significant in most of these trials, prompting a revision to the place of this class of drugs in the treatment algorithms of professional societies [ 57 , 58 ].

also in 53,322 other papers